Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06423235

Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules

A multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial was designed to evaluate the efficacy and safety of Prunella oral liquid in patients with benign thyroid nodules, which belongs to the post-marketing reevaluation clinical study.

In this study, 234 subjects will be enrolled by competitive enrollment at several research centers across China. The main inclusion criteria are:

① Thyroid ultrasound examination found thyroid nodules, can be accompanied by goiter, and the nodules meet the following conditions: 1) There were dominant nodules in single or multiple nodules (the largest diameter of the second largest nodules was not more than 50% of the largest nodules), 2) solid nodules, 3) the longest diameter of nodules was ≥1cm and < 3cm, 4) C-TIRADS 3~4A nodules.

② Patients who met the puncture indication were confirmed by fine needle aspiration biopsy (FNAB) as benign nodules (Bethesda II).

③ Levels of TSH, FT3 and FT4 were normal, and the antibody titers of TgAb and TPOAb were normal.

Eligible subjects will be randomly assigned on a 1:1:2:2 scale to: Group A (placebo conventional dose group, 10 mL/times, 2 times/day), group B (placebo 2x dose group, 10ml/times, 2 times/day), group C (conventional dose group of Prunella oral liquid), group D (Prunella oral liquid 2x dose group). All subjects will receive the treatment for 9 months and follow up at 3rd, 6th, 9th and 12th month.

The primary efficacy endpoint of this study was the rate of change in thyroid nodule volume from baseline at 9 months of treatment. The rate of change in thyroid nodule volume from baseline at 3 and 6 months of treatment was a secondary efficacy endpoint. Other secondary efficacy endpoints included maximum thyroid nodule diameter, number of thyroid nodules, proportion of patients with reduced thyroid nodule volume or ≥50% from baseline, thyroid volume, thyroid function (serum TSH, FT3, FT4, thyroid egg levels (Tg), thyroid antibody levels (TgAb, TPOAb), quality of life evaluation (SF-36), etc. Safety endpoints included incidence of AE/ serious adverse events (SAE), causality, and outcomes. Incidence of AE/SAE leading to discontinuation. Changes in safety laboratory test values from baseline.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Second Hospital of Army Military Medical University, Chongqing, Chongqing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years old ≤65 years old;
  • Thyroid ultrasonography found thyroid nodules, may be accompanied by goiter, and the nodules meet the following conditions: 1) single nodules, or dominant nodules in multiple nodules (the largest diameter of the second largest nodules does not exceed 50% of the largest nodules), 2) solid nodules, 3) the longest diameter of nodules ≥1cm and < 3cm, 4) C-TIRADS 3~4A nodules;
  • Patients who met the puncture indications were confirmed by fine needle aspiration biopsy (FNAB) as benign nodules (Bethesda Class II);
  • Serum TSH, free thyroid hormone (FT3, FT4) levels were normal, anti-thyroglobulin (TgAb) and anti-thyroid peroxidase (TPOAb) antibody titers were normal;
  • Meet the diagnostic criteria of thyroid nodules in TCM;
  • Sign the informed consent.

Exclusion criteria

  • Exclude the patients with Deficiency of Yang syndrome, and the following two conditions can be diagnosed: Shortness of breath, abdominal pain and diarrhea, diarrhea with undigested food, Insufficiency with chills, exhaustion and lethargy, pale tongue and white fur, deep and weak pulse
  • Those who have reproductive needs during pregnancy, lactation and within the last 12 months;
  • Patients with high possibility of thyroid cancer indicated by ultrasonic signs and malignant confirmed by fine needle biopsy;
  • Patients who meet the indications for thyroid nodule surgery, such as local compression symptoms obviously related to the nodule, the tumor is located behind the sternum or in the mediastinum, or strongly require surgery due to appearance or ideological concerns affecting normal life;
  • Patients who have taken prunella preparations or other similar Chinese medicines to treat the disease within the past 1 month; Patients using glucocorticoids in the last 3 months;
  • Patients who have had or plan to take thyroid hormone, iodine compound, or antithyroid drug therapy during the study period;
  • Patients who have previously or plan to undergo ablation, neck radiation, surgery and other non-drug treatments during the study period;
  • Patients with parathyroid tumor (PTA), medullary thyroid cancer (MTC) or other malignant tumors, or patients with serious cardiovascular disease, liver and kidney disease, osteoporosis, or patients with a history of mental illness;
  • Patients with a family history of thyroid cancer or thyroid cancer syndrome;
  • Laboratory test index ALT, AST > 1.5 times the upper limit of reference value or blood creatinine (Scr) > the upper limit of reference value;
  • Persons who are known to be allergic to the investigational drug or its ingredients;
  • Other patients determined by the investigator to be unsuitable for participation in the study.

Treatment and study plan

regular dose of JiRui® Prunella oral liquid

Drug

Take 10ml twice a day

2x regular dose of JiRui® Prunella oral liquid

Drug

Take 20ml twice a day

regular dose of placebo

Drug

Take 10ml twice a day

2x regular dose of placebo

Drug

Take 20ml twice a day

Primary outcomes

  1. Rate of change in thyroid nodule volume from baseline at 9 months of treatment.

    Time frame: 270 ± 14 days

Secondary outcomes

  1. Rate of change in thyroid nodule volume from baseline at 3 months of treatment.

    Time frame: 90 ± 7 days.

  2. Rate of change in thyroid nodule volume from baseline at 6 months of treatment.

    Time frame: 180 ± 10 days.

  3. Rate of change in thyroid nodule volume from baseline at 12 months of treatment.

    Time frame: 360 ± 14 days.

  4. The change value of the maximum diameter of thyroid nodules from baseline at 3 months of treatment.

    Time frame: 90 ± 7 days

  5. The change value of the maximum diameter of thyroid nodules from baseline at 6 months of treatment.

    Time frame: 180 ± 10 days

  6. The change value of the maximum diameter of thyroid nodules from baseline at 9 months of treatment.

    Time frame: 270 ± 14 days

  7. The change value of the maximum diameter of thyroid nodules from baseline at 12 months of treatment.

    Time frame: 360 ± 14 days

  8. Proportion of patients with reduced thyroid nodule volume from baseline at 3 months of treatment.

    Time frame: 90 ± 7 days

  9. Proportion of patients with reduced thyroid nodule volume from baseline at 6 months of treatment.

    Time frame: 180 ± 10 days

  10. Proportion of patients with reduced thyroid nodule volume from baseline at 9 months of treatment.

    Time frame: 270 ± 14 days

  11. Proportion of patients with reduced thyroid nodule volume from baseline at 12 months of treatment.

    Time frame: 360 ± 14 days

  12. Proportion of patients with reduced thyroid nodule volume ≥50% from baseline at 3 months of treatment.

    Time frame: 90 ± 7 days

  13. The proportion of patients with reduced thyroid nodule volume ≥50% from baseline at 6 months of treatment.

    Time frame: 180 ± 10 days

  14. Proportion of patients with reduced thyroid nodule volume ≥50% from baseline at 9 months of treatment.

    Time frame: 270 ± 14 days

  15. Proportion of patients with reduced thyroid nodule volume ≥50% from baseline at 12 months of treatment.

    Time frame: 360 ± 14 days

  16. Changes in the number of thyroid nodules from baseline at the 3 months of treatment.

    Time frame: 90 ± 7 days

  17. Changes in the number of thyroid nodules from baseline at the 6 months of treatment.

    Time frame: 180 ± 10 days

  18. Changes in the number of thyroid nodules from baseline at the 9 months of treatment.

    Time frame: 270 ± 14 days

  19. Changes in the number of thyroid nodules from baseline at the 12 months of treatment.

    Time frame: 360 ± 14 days

  20. Proportion of patients with thyroid nodule progression (greater than 50% in volume or greater than 20% in at least 2 diameters from baseline) at 3 months of treatment.

    Time frame: 90 ± 7 days

  21. Proportion of patients with thyroid nodule progression (greater than 50% in volume or greater than 20% in at least 2 diameters from baseline) at 6 months of treatment.

    Time frame: 180 ± 10 days

  22. Proportion of patients with thyroid nodule progression (greater than 50% in volume or greater than 20% in at least 2 diameters from baseline) at 9 months of treatment.

    Time frame: 270 ± 14 days

  23. Proportion of patients with thyroid nodule progression (greater than 50% in volume or greater than 20% in at least 2 diameters from baseline) at 12 months of treatment.

    Time frame: 360 ± 14 days

  24. Rate of change in thyroid volume from baseline at 3 months of treatment.

    Time frame: 90 ± 7 days

  25. Rate of change in thyroid volume from baseline at 6 months of treatment.

    Time frame: 180 ± 10 days

  26. Rate of change in thyroid volume from baseline at 9 months of treatment.

    Time frame: 270 ± 14 days

  27. Rate of change in thyroid volume from baseline at 12 months of treatment.

    Time frame: 360 ± 14 days

  28. Changes in serum TSH, FT3 and FT4 from baseline at the months of treatment.

    Time frame: 90 ± 7 days

  29. Changes in serum TSH, FT3 and FT4 from baseline at the months of treatment.

    Time frame: 180 ± 10 days

  30. Changes in serum TSH, FT3 and FT4 from baseline at 9 months of treatment.

    Time frame: 270 ± 14 days

  31. Changes in serum TSH, FT3 and FT4 from baseline at 12 months of treatment.

    Time frame: 360 ± 14 days

  32. Changes in Tg, TgAb and TPOAb levels from baseline at the 6th month of treatment.

    Time frame: 180 ± 10 days

  33. Proportion of patients with normal thyroid function at 3 months of treatment.

    Time frame: 90 ± 7 days

  34. Proportion of patients with normal thyroid function at 6 months of treatment.

    Time frame: 180 ± 10 days

  35. Proportion of patients with normal thyroid function at 9 months of treatment.

    Time frame: 270 ± 14 days

  36. Proportion of patients with normal thyroid function at 12 months of treatment.

    Time frame: 360 ± 14 days

  37. Subjects' quality of life scores (SF-36) at 3 months of treatment.

    Time frame: 90 ± 7 days

  38. Subjects' quality of life scores (SF-36) at 6 months of treatment.

    Time frame: 180 ± 10 days

  39. Subjects' quality of life scores (SF-36) at 9 months of treatment.

    Time frame: 270 ± 14 days

  40. Subjects' quality of life scores (SF-36) at 12 months of treatment.

    Time frame: 360 ± 14 days

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Xintian Pharmaceutical

Industry

Registry information

Official study title

Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules: a Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study

Acronym: ESPTTN

Important dates

Study start
2024
Primary completion
2025
Study completion
2028
First posted
May 21, 2024
Registry last updated
Mar 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.